Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-08-09
2011-08-09
Crane, Lawrence E (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500, C536S025200
Reexamination Certificate
active
07994152
ABSTRACT:
A method of treating a tumor or a viral disease by administering to a human the following 2′,5′-oligoadenylate analog:Wherein m is 0; n is 0 or 1; R1is alkoxy substituted by hydroxyl, mercapto, alkylthio substituted by hydroxyl or X1—X2—X3—S—; R2, R3, R4, R5and R6are hydroxyl, mercapto, alkylthio substituted by hydroxyl or X1—X2—X3—S—; R7is oxygen, sulfur, —NH—, or —O(CH2CH2O)q-, wherein q is 2 to 6, or oxyalkyleneoxy; R8is hydrogen or a 5′-phosphorylated oligonucleotide which has one hydroxyl removed from the 5′-phosphoric acid; E1is K2; E2is K1; E3is K2or K3and E4is K1, K2or K3; K1isK2isK3isB is adeninyl; A is alkylene;D is alkyl or alkenyl; X1is alkyl or phenyl; X2is —C(═O)O—, —OC(═O)— or —C(═O)S—; and X3is alkylene.
REFERENCES:
patent: 7651999 (2010-01-01), Koizumi et al.
patent: 1 013 661 (2000-06-01), None
patent: 1 152 009 (2001-11-01), None
patent: 10-195098 (1998-07-01), None
patent: 10-304889 (1998-11-01), None
patent: 2000-297097 (2000-10-01), None
patent: 3420984 (2000-10-01), None
patent: 2002-249497 (2002-09-01), None
patent: WO 89/12380 (1989-12-01), None
patent: WO 01/22970 (2001-04-01), None
English-language translation of Notification of Reasons for Refusal dated Mar. 2, 2010 in JP 2003-388199.
English-language translation of Decision of Refusal dated Jul. 1, 2010 in JP 2003-388199.
Canadian Office Action dated Jul. 5, 2010 in Canadian application 2,506,581.
K. Lesiak et al., “2′,5′-Oligoadenylate: Antisense Chimeras-Synthesis and Properties,”BioconjugateChem., (1993), 4, 467-472.
English-language summary of Colombian Office Action in Colombian application 05048112, May 18, 2005.
C. Battistini et al., “An Efficient and Stereoselective Synthesis of 2′,5′-Oligo-(Sp)-Thioadenylates,”Tetrahedron, vol. 48, No. 15, pp. 3209-3226, (1992).
Mark R. Player et al., “The 2-5A System: Modulation of Viral and Cellular Processes Through Acceleration of RNA Degradation,”Pharmacol. Ther., vol. 78, No. 2, pp. 55-113, (1998).
Lorraine Rusch, “Caspase-Dependent Apoptosis by 2′,5′-Oligoadenylate Activation of RNase L is Enhanced by IFN-β,”J. Interferon Cytokine Res., 20, pp. 1091-1100, (2000).
Robert W. Sobol et al., “Inhibition of HIV-1 Replication and Activation of RNase L by Phosphorothioate/Phosphodiester 2′,5′-Oligoadenylate Derivatives”J. Biol. Chem., vol. 270, No. 11, pp. 5963-5978, (1995).
Susan M. Freier et al., “The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes,”Nucleic Acids Research, vol. 25, No. 22, pp. 4429-4443, (1997).
J. Carpten et al., “Germline mutations in the ribonuclease L gene in families showing linkage with HPC1,”Nat. Genetics, vol. 30, No. 2, pp. 181-184, (2002).
Steven A. Adah et al., “Chemistry and Biochemistry of 2′,5′-Oligoadenylate-Based Antisense Strategy,”Curr. Med. Chem., 8, pp. 1189-1212, (2001).
Masamitu Shimazu et al., “Regio- and stereocontrolled synthesis of 2′-5′ linked phosphorothioate oligoadenylates by uranyl ion catalyst in aqueous solution,”J. Chem. Soc. Perkin Trans., No. 15, pp. 1778-1785, (2002).
Sharon Naik et al., “RNase L dimerization in a mammalian two-hybrid system in response to 2′,5′-oligoadenylates,”Nucl. Acid Res., vol. 26, No. 6, pp. 1522-1527, (1998).
Wei Xiao et al., “Synthesis of a 5′-Thiophosphate Analogue of 2-5A, A Phosphatase Resistant Activator of the 2-5A-Dependent Ribonuclease ”Bioorg. Med. Chem. Let., vol. 4, No. 21, pp. 2609-2614, (1994).
D. Watling et al., “Analogue inhibitor of 2-5A action: effect on the interferon-mediated inhbition of encephalomyocarditis virus replication,”The EMBO. J., vol. 4, No. 2, pp. 431-436, (1984).
Paul F. Torrence et al., “Oligonucleotide Structural Parameters That Influence Binding of 5′-O-Triphosphoadenylyl-(2′-5′)-adenylyl-(2′-5′)-adenosine to the 5′-O-Triphosphoadenyly1-(2′-5′)-adenylyl-(2′-5′)-adenosine Dependent Endoribonuclease: Chain Length, Phosphorylation State, and Heterocyclic Base,”J. Med. Chem., vol. 27, pp. 726-733, (1984).
Margaret Haugh et al., “Analogues and Analogue Inhibitors of ppp (A2′p)nA Their Stability and Biological Activity,”,Eur. J. Biochem., vol. 132, No. 1, pp. 77-84, (1983).
Simon S. Jones et al., “Chemical Synthesis of 5′-O-Triphosphoryladenylyl-(2′-5′)-adenylyl-(2′-5′)-adenosine (2-5A),”J. Amer Chem. Soc., vol. 24, pp. 7399-7401, (1979).
Ying Xiang et al., “Effects of RNase L Mutations Associated with Prostste Cancer on Apoptosis Induced by 2′,5′-Oligoadenylates,”,Cancer Res., vol. 63, No. 20, pp. 6795-6801, (2003).
Yoshihito UENO et al., “Synthesis of the antisense oligonucleotides carrying the modified 2-5A molecules at their 5′-termini and their properties,”Nucl. Acid Res., Suppl.No. 2, pp. 45-46, (2002).
English-language International Preliminary Examination Report dated May 12, 2005 of International application PCT/JP2003/014748 filed Nov. 19, 2003 Applicant: Sankyo Company, Ltd.
Koizumi Makoto
Morita Koji
Crane Lawrence E
Holtz Holtz Goodman & Chick PC
Sankyo Company Limited
LandOfFree
Method of treating a cancer by administering A... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating a cancer by administering A..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating a cancer by administering A... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2741668